Relief Therapeutics Holding AG (RLFTF)

[nelskof]

From Dr Javitt's comments about the role of the DMC they can only make 4 decisions.

1. Stop the trial due to safety concerns
2. Stop the trial due to a lack of efficacy
3. Continue the trial because they believe it can meet it's end points
4. End the trial because the evidence is so overwhelming it's unethical to continue placebo

Can't we assume it's #3 just based off Dr Javitt's comments that the trial would be unblinded in about a month? The other options are to end the trial and we know that didn't happen.

What info are you hoping to glean from the interim update? Serious question because biopharma's are not an ordinary investment for me. The PR after the DMC looked at 30 patients only said #3 from above.